Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1979 May;36(2):237–243.

Intravenous immunoglobulin therapy for antibody deficiency.

M T Nolte, B Pirofsky, G A Gerritz, B Golding
PMCID: PMC1537711  PMID: 477026

Abstract

Twenty patients with antibody deficiency were treated at random with either intramuscular immune serum globulin (ISG) or intravenous modified immune serum globulin (M-ISG). Fourteen patients received of 259 M-ISG infusions during 242 months of treatment. Catastrophic vasomotor reactions were not observed. A single dose of 150 mg/kilo M-ISG increased serum IgG values a mean 248 mg%. Intravenous M-ISG therapy was effective in reducing the incidence of acute infections. Subjects receiving M-ISG developed 0.103 acute infections per month of treatment. Patients injected with ISG had 0.295 acute infections per month of treatment. Seven subjects had separate courses of both intravenous M-ISG and intramuscular ISG. Acute infections per month of treatment for M-ISG and ISG were 0.104 and 0.406, respectively.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARANDUN S., KISTLER P., JEUNET F., ISLIKER H. Intravenous administration of human gamma-globulin. Vox Sang. 1962;7:157–174. doi: 10.1111/j.1423-0410.1962.tb03240.x. [DOI] [PubMed] [Google Scholar]
  2. DOMZ C. A., DICKSON D. R. The agammaglobulinemias; relations and implications. Am J Med. 1957 Dec;23(6):917–927. doi: 10.1016/0002-9343(57)90302-9. [DOI] [PubMed] [Google Scholar]
  3. GITLIN D., JANEWAY C. A. Agammaglobulinemia, congenital, acquired and transient forms. Prog Hematol. 1956;1:318–329. [PubMed] [Google Scholar]
  4. Hitzig W. H., Müntener U. Conventional immunoglobulin therapy. Birth Defects Orig Artic Ser. 1975;11(1):339–342. [PubMed] [Google Scholar]
  5. Ishizaka T., Ishizaka K., Salmon S., Fudenberg H. Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes. J Immunol. 1967 Jul;99(1):82–91. [PubMed] [Google Scholar]
  6. Janeway C. A., Merler E., Rosen F. S., Salmon S., Crain J. D. Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med. 1968 Apr 25;278(17):919–923. doi: 10.1056/NEJM196804252781701. [DOI] [PubMed] [Google Scholar]
  7. Janeway C. A., Rosen F. S. The gamma globulins. IV. Therapeutic uses of gamma globulin. N Engl J Med. 1966 Oct 13;275(15):826–831. doi: 10.1056/NEJM196610132751508. [DOI] [PubMed] [Google Scholar]
  8. Koblet H., Barandun S., Diggelmann H. Turnover of standard-gammaglobulin, pH-4-gammaglobulin and pepsin desaggregated gammaglobulin and clinical implications. Vox Sang. 1967 Jul;13(1):93–102. [PubMed] [Google Scholar]
  9. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  10. Merler E., Rosen F. S., Salmon S., Crain J. D., Janeway C. A. Studies with intravenous gamma globulin. Vox Sang. 1967 Jul;13(1):102–103. [PubMed] [Google Scholar]
  11. Painter R. H., Walcroft M. J., Weber J. C. The efficacy of fragmented immune serum globulin in passive immunization. Can J Biochem. 1966 Mar;44(3):381–387. doi: 10.1139/o66-045. [DOI] [PubMed] [Google Scholar]
  12. SCHULTZE H. E., SCHWICK G. [On new possibilities of intravenous gamma globulin administration]. Dtsch Med Wochenschr. 1962 Aug 24;87:1643–passim. doi: 10.1055/s-0028-1113997. [DOI] [PubMed] [Google Scholar]
  13. Sgouris J. T. The preparation of plasmin treated immune serum globulin for intravenous use. Vox Sang. 1967 Jul;13(1):71–84. [PubMed] [Google Scholar]
  14. Smith G. N., Griffiths B., Mollison D., Mollison P. L. Uptake of IgG after intramuscular and subcutaneous injection. Lancet. 1972 Jun 3;1(7762):1208–1212. doi: 10.1016/s0140-6736(72)90926-9. [DOI] [PubMed] [Google Scholar]
  15. Stephan W., Hainski M., Payne J. H., Ordonez G. A., Shanbrom E. Undegraded -globulin for intravenous therapy. A new preparation of immune serum globulin for intravenous administration. Vox Sang. 1971 May;20(5):469–478. doi: 10.1111/j.1423-0410.1971.tb01827.x. [DOI] [PubMed] [Google Scholar]
  16. Wells J. V., Penny R. Survival studies on a commercial preparation of intravenous human gammaglobulin labelled with 131-I. Australas Ann Med. 1969 Aug;18(3):271–276. doi: 10.1111/imj.1969.18.3.271. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES